|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Peg-Intron[派樂能] information |
|
|
|
製造商 |
Schering-Plough |
|
代理/經銷商 |
Arich |
|
成份 |
Peginterferon α-2b |
|
適應症 |
Chronic hepatitis C. |
|
用量 |
Adult ≥18 years Monotherapy 0.5 or 1 mcg/kg SC once weekly for at least 6 months. Combination therapy 1.5 mcg/kg SC once weekly in combination with ribavirin. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
禁忌 |
Hypersensitivity to interferon. Pregnancy. Men whose female partners are pregnant. Autoimmune hepatitis or a history of autoimmune disease. Decompensated liver disease or severe renal dysfunction. |
|
注意事項 |
Existence of or history of severe psychiatric conditions, history of CHF, MI &/or previous arrhythmic disorders, acute hypersensitivity reactions, renal & hepatic impairment. Maintain adequate hydration since hypotension related to fluid depletion may occur. Pulmonary changes, autoimmune disease. Periodic visual exam during therapy is recommended. Thyroid changes. Monitor lipid levels. Psoriasis or sarcoidosis. May impair ability to drive or operate machinery. Lactation. Children < 18 years. Lactation. |
|
不良反應 |
Very common: Pain/inflammation at the inj site, fatigue, rigors, fever, depression, arthralgia, nausea, alopecia, musculoskeletal pain, irritability, flu-like symptoms, insomnia, diarrhea, abdominal pain, asthenia, pharyngitis, decreased weight, anorexia, anxiety, impaired concentration, dizziness, inj site reaction, tachycardia, rhinitis, taste perversion. Common: Pruritus, dry skin, malaise, increased sweating, right upper quadrant pain, neutropenia, leukopenia, anemia, rash, vomiting, dry mouth, emotional lability, nervousness, dyspnea, viral infection, somnolence, thyroid disorders, chest pain, dyspepsia, flushing, paresthesia, coughing, agitation, sinusitis, hypertonia, hyperesthesia, blurred vision, confusion, flatulence, decreased libido, erythema, eye pain, apathy, hypoesthesia, loose stool, conjunctivitis, nasal congestion, constipation, vertigo, menorrhagia, menstrual disorder, hypotension, syncope, HTN, lacrimal gland disorder, tremor, gingival bleeding, glossitis, stomatitis, ulcerative stomatitis, hearing impairment/loss, tinnitus, palpitation, thirst, aggressive behavior, fungal infection, prostatitis, otitis media, bronchitis, resp disorder, rhinorrhea, eczema, abnormal hair texture, photosensitivity reaction, lymphadenopathy.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Drugs metabolised by CYP 1A2 enzyme system, CYP2C8/9 & CYP2D6, highly active antiretroviral therapy.
View more drug interactions with Peg-Intron[派樂能] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Peg-Intron 乾粉注射劑 |
|
Peg-Intron 50 mcg x 1's |
|
Peg-Intron 80 mcg x 1's |
|
Peg-Intron 100 mcg x 1's |
|
Peg-Intron 120 mcg x 1's |
|
|
Peg-Intron 筆式注射劑 |
|
Peg-Intron 50 mcg/0.5 mL x 1's |
|
Peg-Intron 80 mcg/0.5 mL x 1's |
|
Peg-Intron 100 mcg/0.5 mL x 1's |
|
Peg-Intron 120 mcg/0.5 mL x 1's |
|
|
|
Manufacturer: |
Schering-Plough |
|
Distributor: |
Arich |
|
|
|
|
|
